HD-OPM Archive
Hashtags

#apoa1

4 posts

HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal

Mar 11, 2024 · Louis Nervegna ♥ 6 · 💬 9 ↩ 22 LDL, ApoB & lipid panel

Louis reviews why HDL or ApoA-I is probably not causal for heart disease. CETP inhibitor trials failed (ILLUMINATE with torcetrapib was stopped for harm; dal-OUTCOMES with dalcetrapib and ACCELERATE with evacetrapib showed no benefit), as did fibrate and niacin trials and CSL112 infusions, and Mendelian randomization agrees. He proposes HDL and ApoA-I mainly act as a proxy for insulin sensitivity, which is the real causal factor.

CSL112 ApoA-I infusion failed in phase 3 AEGIS-II, supporting HDL as marker not cause

Feb 13, 2024 · Louis Nervegna ♥ 8 · 💬 5 ↩ 14 LDL, ApoB & lipid panel

Louis argues the failure of AEGIS-II, in which patients received native ApoA-I (CSL112), shows ApoA-I is not directly causal in heart disease. Every large pharmaceutical trial raising HDL or ApoA-I has failed to prevent heart attacks and strokes. HDL and ApoA-I remain good risk markers, probably standing in for insulin resistance, so raising them by means other than improving insulin sensitivity may not lower risk.

Why insulin resistance lowers HDL, and why improving insulin sensitivity beats chasing HDL

Mar 21, 2024 · Louis Nervegna ♥ 5 ↩ 10 LDL, ApoB & lipid panel

Louis lists six mechanisms by which insulin resistance lowers HDL: impaired HDL maturation (lower LCAT), reduced apoA-I production, faster HDL catabolism (hepatic lipase, CETP), altered HDL composition and function, higher triglycerides making small dense HDL, and inflammation and oxidative stress. He concludes the best way to raise HDL is improving insulin sensitivity (lose visceral fat, exercise, cut refined starch and sugar), since insulin resistance is causal in heart disease while large RCTs suggest HDL itself is probably not.